Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
- 26 Juin 2024 - 1 mn de lecture
The purpose of this study was to demonstrate the safety and the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as BTX-A-HAC Next Generation (BTX-A-HAC NG)), used for the improvement in the appearance of moderate to severe glabellar lines (the lines between the eyebrows).
26 Juin 2024
1 mn de lecture
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
26 Juin 2024
1 mn de lecture
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
26 Juin 2024
1 mn de lecture
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
26 Juin 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
26 Juin 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Follow-on Study
26 Juin 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Study
26 Juin 2024
1 mn de lecture
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
26 Juin 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Study
26 Juin 2024
1 mn de lecture
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
26 Juin 2024
1 mn de lecture